 NEW YORK, Oct. 26, 2020 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration FDA has cleared the Companys Investigational New Drug IND application for 177Lu-omburtamab-DTPA for the treatment of B7-H3 positive Central Nervous System CNS and Leptomeningeal Metastasis LM from tumors in adult patients. 